List view / Grid view
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
27 September 2013 | By Novartis
Pivotal myopic CNV trials with Lucentis® (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year...
27 September 2013 | By GlaxoSmithKline
GlaxoSmithKline (GSK) and Barclays have formed a new partnership which aims to increase access to affordable healthcare and medicines for people in Zambia...
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced today that veterinarians and farmers across the globe have reached the milestone of protecting more than 500 million pigs from the potentially devastating consequences of Mycoplasma hyopneumonia...
27 September 2013 | By AstraZeneca
AstraZeneca today announced that the European Medicines Agency (EMA) has accepted its Marketing Authorisation Application (MAA) for olaparib...
27 September 2013 | By Cancer Research UK
A US-led initiative to map the molecular similarities and differences of thousands of tumours has revealed new ways to classify cancer...
27 September 2013 | By Boehringer Ingelheim
Boehringer Ingelheim has inaugurated the building of its chemicals R&D laboratory Center of Competence in the Zhangjiang High-Tech Park in Shanghai...
27 September 2013 | By Genzyme
18 platform and poster presentations provide deeper insight into the Clinical Development Programs for Aubagio® and Lemtrada™...
27 September 2013 | By Gilead Sciences, Inc.
Tybost™ is a new Bbosting agent for HIV therapy which facilitates once-daily dosing of the protease inhibitors Atazanavir and Darunavir...
27 September 2013 | By Takeda Pharmaceutical Company Limited
TAK-816 is a Haemophilus Influenzae type b (Hib) vaccine...
27 September 2013 | By AstraZeneca
Naloxegol is an investigational peripherally-acting mu-opioid receptor antagonist designed for the treatment of opioid-induced constipation (OIC)...
27 September 2013 | By Teva Pharmaceutical Industries Ltd
Series of events throughout Congress to shed light on new data and evolving MS landscape...
26 September 2013 | By Penn Pharma
A £14 million state-of-the-art facility formally opened...
25 September 2013 | By Cancer Research UK
Trio enter into an agreement to co-fund the further development of a class of cancer drugs called CHK1 inhibitors.
25 September 2013 | By Bristol-Myers Squibb Company
At 24 weeks in patients with Type 2 diabetes inadequately controlled with the combination of Metformin Plus Sulfonylurea...
